Review
Oncology
Eelco de Bree, Dimosthenis Michelakis, Elisavet Anagnostopoulou
Summary: Ovarian cancer is the second most common and fatal gynecological malignancy worldwide, with most patients presenting in advanced stages. Cytoreductive surgery in combination with platinum-based chemotherapy is the standard treatment. Despite advancements, recurrence and death from the disease are still common. The role of secondary cytoreductive surgery in recurrent ovarian cancer is controversial and should be continuously reviewed.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Myeong-Seon Kim, Seung Hun Baek, Joseph J. Noh, Jung In Shim, Jun Hyeok Kang, Soo Young Jeong, Chel Hun Choi, Tae-Joong Kim, Jeong-Won Lee, Yoo-Young Lee
Summary: This study investigated the incidence of reactive thrombocytosis and its impact on survival in patients with advanced epithelial ovarian cancer (EOC) after maximal cytoreductive surgery. The results showed that thrombocytosis was observed in 34.8% of patients one week after surgery, and it had the most significant effects on overall survival when observed during adjuvant chemotherapy.
FRONTIERS IN ONCOLOGY
(2022)
Review
Oncology
Claudia Marchetti, Anna Fagotti, Vincenzo Tombolini Fp, Giovanni Scambia Fp, Francesca De Felice
Summary: This study compared secondary cytoreductive surgery followed by systemic therapy with systemic therapy alone for recurrent ovarian cancer patients. The results showed that secondary cytoreductive surgery was associated with significantly better progression-free survival (PFS) improvement, especially for the complete resection subpopulation. Overall survival (OS) was similar between the groups, but favored the complete resection subpopulation.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Article
Oncology
Minjun He, Yuerong Lai, Hongyu Peng, Chongjie Tong
Summary: The therapeutic value of lymphadenectomy in patients with advanced ovarian cancer undergoing neoadjuvant chemotherapy followed by interval debulking surgery remains unclear. Residual disease >=1cm and elevated CA125 levels after 3 cycles of adjuvant chemotherapy were identified as negative predictors for overall survival.
FRONTIERS IN ONCOLOGY
(2021)
Review
Oncology
Francesco Guida, Shayan Dioun, Anna Fagotti, Alexander Melamed, Adriano Grossi, Giovanni Scambia, Jason D. Wright, Ana I. Tergas
Summary: This study evaluates the clinical utility of tertiary cytoreductive surgery in recurrent ovarian cancer through a systematic review and meta-analysis. The results show that optimal tertiary cytoreductive surgery is associated with improved disease specific survival and overall survival compared to suboptimal tertiary cytoreductive surgery.
GYNECOLOGIC ONCOLOGY
(2022)
Article
Oncology
Kirsten Jorgensen, Alexander Melamed, Chi-Fang Wu, Roni Nitecki, Rene Pareja, Anna Fagotti, John O. Schorge, Pedro T. Ramirez, Jose Alejandro Rauh -Hain
Summary: This study aimed to assess the outcomes of interval debulking surgery (IDS) after neoadjuvant chemotherapy via minimally invasive surgery (MIS) compared with laparotomy in patients with advanced epithelial ovarian cancer. The study found that patients who underwent IDS with MIS had similar overall survival and decreased morbidity compared with those who underwent laparotomy.
GYNECOLOGIC ONCOLOGY
(2023)
Correction
Medicine, General & Internal
Philipp Harter, Jalid Sehouli, Ignace Vergote, Gwenael Ferron, Alexander Reuss, Werner Meier, Stefano Greggi, Berit J. Mosgard, Frederic Selle, Frederic Guyon, Christophe Pomel, Fabrice Lecuru, Rongyu Zang, Elisabeth Avall-Lundqvist, Jae-Weon Kim, Jordi Ponce, Francesco Raspagliesi, Gunnar Kristensen, Jean-Marc Classe, Peter Hillemanns, Pernille Jensen, Annette Hasenburg, Sadaf Ghaem-Maghami, Mansoor R. Mirza, Bente Lund, Alexander Reinthaller, Ana Santaballa, Adeola Olaitan, Felix Hilpert, Andreas du Bois
Summary: In patients with recurrent ovarian cancer, cytoreductive surgery followed by chemotherapy resulted in longer overall survival than chemotherapy alone. Patients with a complete resection had the most favorable outcome.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Oncology
Estelle Turrel, Nicolas Chopin, Pierre Meeus, Anna Blache, Isabelle Ray-Coquard, Olivier Tredan, Isabelle Treilleux, Coralie Ebring, Mellie Heinemann, Lea Rossi
Summary: Cytoreductive surgery is crucial in the treatment of ovarian cancer, but it may lead to significant morbidity. However, achieving no residual tumor (CC-0) has been shown to improve prognosis. This study found that postoperative pathological analysis often does not overestimate peritoneal involvement, and the potential surgical morbidity associated with peritoneal resection in IDS is acceptable.
Article
Oncology
Joo-Hyuk Son, Jimin Lee, Sun-Hyung Yum, Jeeyeon Kim, Tae-Wook Kong, Suk-Joon Chang, Hee-Sug Ryu
Summary: This study evaluated the clinical characteristics of 262 patients with recurrent ovarian cancer to identify factors associated with the selection of patients who would benefit from secondary cytoreductive surgery (SCS). The study found that patients who received SCS had significantly longer median survival compared to those who received chemotherapy alone. Limited regional recurrence emerged as a simplified factor for predicting no residual disease after SCS.
Article
Biochemistry & Molecular Biology
Andrea Plaja, Iris Teruel, Maria Ochoa-de-Olza, Marc Cucurull, Alvaro Javier Arroyo, Beatriz Pardo, Irene Ortiz, Marta Gil-Martin, Josep Maria Piulats, Helena Pla, Claudia Fina, Anna Carbo, Maria-Pilar Barretina-Ginesta, Sergio Martinez-Roman, Elvira Carballas, Andrea Gonzalez, Anna Esteve, Margarita Romeo
Summary: Despite a multimodal radical treatment, mortality of advanced epithelial ovarian cancer (AEOC) remains high. This study investigates the prognostic value of neutrophil, monocyte, and platelet to lymphocyte ratios (NLR, MLR, PLR) in newly diagnosed AEOC patients undergoing primary debulking surgery (PDS) or interval debulking surgery (IDS). The results suggest that NLR and PLR may have prognostic value in PDS, but not in IDS.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Nicolo Bizzarri, Claudia Marchetti, Carmine Conte, Matteo Loverro, Maria Teresa Giudice, Lorena Quagliozzi, Mariagrazia Distefano, Vito Chiantera, Giovanni Scambia, Anna Fagotti
Summary: The present study aimed to evaluate the oncological outcomes of platinum-sensitive recurrent ovarian cancer patients undergoing secondary cytoreduction (SCS) after treatment with neoadjuvant chemotherapy (NACT) and interval debulking surgery (IDS) at diagnosis, and to compare the performance of different selection models in these patients. It was found that patients treated with NACT/IDS had similar post-recurrence survival outcomes compared to those treated with primary debulking surgery (PDS), and the current selection models could be safely applied to IDS patients.
GYNECOLOGIC ONCOLOGY
(2022)
Article
Oncology
Leen Verleye, Diego Castanares-Zapatero, Carl Devos, Cindy De Gendt, Geert Silversmit, Nancy Van Damme, Frank Hulstaert, Nancy Thiry, Mattias Neyt
Summary: In a study conducted in Belgium, researchers found that despite an increase in the use of debulking surgery and bevacizumab in the treatment of advanced ovarian cancer, there was no significant improvement in the 3-year survival probability for patients.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2023)
Review
Oncology
Alexander Melamed, Eric L. Eisenhauer
Summary: With the increasing use of neoadjuvant chemotherapy, it is apparent that some patients may benefit from less extensive interval cytoreductive surgery performed using minimally invasive techniques. Surgeons in various countries, including the United States, have started adopting these techniques based on their expertise in minimally invasive surgery for other indications in gynecologic oncology. Further research will determine the most suitable patients for this approach.
JOURNAL OF SURGICAL ONCOLOGY
(2023)
Article
Multidisciplinary Sciences
Antoni Llueca, Maria Teresa Climent, Javier Escrig, Paula Carrasco, Anna Serra, L. Gomez-Quiles, R. Jativa, G. Cebrian, V Bosso, A. Villarin, K. Maiocchi, K. Delgado-Barriga, M. Rodrigo-Aliaga, N. Ruiz, C. Herrero, A. Frances, I Beato, C. Ferrer, J. P. Aracil, E. Boldo, A. Boldo, R. Adell
Summary: This study validated the predictive value of three models for predicting suboptimal cytoreductive surgery in advanced ovarian cancer, showing better reliability in predicting complete cytoreductive surgery.
SCIENTIFIC REPORTS
(2021)
Article
Oncology
Soo Jin Park, Eun Ji Lee, Taek Sang Lee, Kung-Liahng Wang, Aikou Okamoto, Kazunori Ochiai, Hee Seung Kim, Jae-Weon Kim
Summary: In Asia, the practice patterns in debulking surgery for advanced ovarian cancer often lean towards relatively lenient criteria for optimal debulking surgery and a preference for neoadjuvant chemotherapy. Many practitioners still rely on aggressive surgery performed by specialists.
